Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Deep molecular response to gilteritinib in CHRYSALIS trial

Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )
23 Jun 2017

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017

Clinical potential of trastuzumab biosimilar CTP6

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA
Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )
8 Jun 2017

Updates in melanoma: Treating BRAF and brain metastases

Prof Georgina Long - University of Sydney, Sydney, Australia
Updates in melanoma: Treating BRAF and brain metastases ( Prof Georgina Long - University of Sydney, Sydney, Australia )
5 Jun 2017

Alectinib eclipses crizotinib for ALK positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA
Alectinib eclipses crizotinib for ALK positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )
5 Jun 2017

Targeted sequencing in endocrine refractory breast cancer

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada
Targeted sequencing in endocrine refractory breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )
5 Jun 2017

Results from the APHINITY trial of two HER2 targeted agents with chemo

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany
Results from the APHINITY trial of two HER2 targeted agents with chemo ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )
5 Jun 2017

Nivolumab and ipilimumab for metastatic sarcoma

Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA
Nivolumab and ipilimumab for metastatic sarcoma ( Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA )
4 Jun 2017

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain
Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )
4 Jun 2017

Phase III results of olaparib for BRCA breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA
Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )
4 Jun 2017

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy
Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )
4 Jun 2017